ProTom International received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Radiance 330 proton therapy system

ProTom International received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Radiance 330 proton therapy system installed at Massachusetts General Hospital (MGH) in Boston, Mass.

The Radiance 330 proton therapy system at MGH is a compact, single room system equipped with an advanced pencil beam scanning system and integrated imaging and control system. The Radiance 330 compact synchrotron can be installed within an interior accelerator vault space of 20′ x 30′ and requires up to 40 percent less radiation shielding.

By using the advanced pencil beam scanning technology, modular designed treatment system and the compact synchrotron particle accelerator, Radiance 330 is a smaller, lighter and cleaner system.

"We are delighted to have received the marketing authorization for the Radiance 330 proton therapy system installed at MGH. The receipt of 510(k) clearance is the final culmination of a thorough and rigorous FDA review of the safety and effectiveness of our compact proton therapy solution," said Steve Spotts, Chief Executive Officer and co-founder of ProTom International. "This achievement accelerates ProTom's single and relentless mission to place this highly sophisticated and targeted cancer-fighting tool within reach of many more physicians. Our team couldn't be more proud of reaching this milestone and will continue our work to advance the delivery of proton therapy while driving down the cost of this much-needed technology."

For more information: https://www.protominternational.com


Related Content

News | Quality Assurance (QA)

February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...

Time February 12, 2024
arrow
Videos | RSNA

At RSNA23, Imaging Technology News (ITN) spoke with Bhvita Jani, principal analyst at Signify Research, about ...

Time February 07, 2024
arrow
News | Interventional Radiology

February 6, 2024 — RenovoRx, Inc., a clinical-stage biopharmaceutical company developing novel precision oncology ...

Time February 06, 2024
arrow
News | Treatment Planning

February 2, 2024 — RaySearch Laboratories announced that the number of radiotherapy centers that have chosen RayStation ...

Time February 02, 2024
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

It's a new year, and as another month comes to a close, ITN takes a look at the Top 10 most-read pieces of content from ...

Time February 01, 2024
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

Did you know that Imaging Technology News (ITN) maintains more than 40 comparison charts of product specifications from ...

Time January 29, 2024
arrow
News | Digital Pathology

January 26, 2024 — New research funded by the National Institute for Health and Care Research (NIHR) has led to the UK ...

Time January 26, 2024
arrow
News | Proton Therapy

January 26, 2024 — P-Cure continues its quest to successfully usher in a new era of clinical treatment with proton ...

Time January 26, 2024
arrow
News | Artificial Intelligence

January 24, 2024 — Nonfunctional pancreatic neuroendocrine tumors, while rare, are primarily treated through surgery ...

Time January 24, 2024
arrow
News | Radiopharmaceuticals and Tracers

January 23, 2024 — IBA, a world leader in particle accelerator technology and the world’s leading provider of ...

Time January 23, 2024
arrow
Subscribe Now